Developing Antitussive Alternatives To DXM Would Offset Commercial Risk
This article was originally published in The Tan Sheet
Executive Summary
Expert advisors to FDA encourage firms to develop new OTC cough suppressants to replace dextromethorphan, which some argue is ineffective and poses an abuse risk